Pershing Square Founder Bill Ackman Claims Lasting Effects from Daughter's Mitochondrial Eye Injection
Bill Ackman, founder of Pershing Square, stated that his daughter continues to observe benefits from autologous mitochondrial intraocular injections, although the effects are weaker than the immediate response post-injection. The team is researching ways to increase the frequency of injections.
This statement corresponds to an exploratory treatment for patients with severe bilateral vision loss: the research team extracted the patient's own mitochondria from skeletal muscle in the leg and subsequently injected active mitochondria into the vitreous cavity of both eyes. Research materials indicate that Bill Ackman previously referred to the patient as his daughter, Lucy; the treatment aims to supplement the energy metabolism capacity of damaged but still viable retinal and optic nerve cells.
Existing public data comes from a single-case, non-randomized, uncontrolled preprint case report that has not yet completed peer review. The patient was nearly blind after optic nerve and retinal damage from a brain hemorrhage; 45 consecutive pupil measurements over 71 days prior to treatment did not reach the preset normal light response threshold, but normal range responses appeared post-injection, with 13 out of 52 subsequent measurements reaching the threshold.
The efficacy does not equate to vision restoration. The study recorded the appearance of pupil light responses within days post-injection, and organized responses to visual stimuli were also observed in the brain's visual evoked potentials; the patient reported shape and shadow perception in the left eye during low vision assessments. However, the study did not observe measurable vision improvement, and the immediate light response weakened approximately four weeks later.
Short-term safety is the main known outcome of this case. After injections in both eyes spaced 24 hours apart, researchers did not report intraocular inflammation, increased intraocular pressure, intraocular infection, retinal detachment, or detectable systemic inflammatory responses; this only supports the feasibility and short-term tolerability of the procedure for a single patient and does not prove that repeated injections are equally safe or that the treatment is effective.
The "increased injection frequency" mentioned by Ackman is currently a research direction, not an approved treatment protocol. Public information does not disclose the planned dosing intervals, dosages, trial design, ethical review status, FDA regulatory pathway, or subject recruitment information; any repeated intraocular injections must be individually assessed for risks of infection, intraocular pressure, retinal damage, and immune responses.
In market mechanisms, mitochondrial transplantation has not yet formed an approved ophthalmic therapy, and its current value is primarily concentrated in scientific validation, patents, hospital research platforms, cell preparation, and clinical trial capabilities. If funding continues to flow in this direction, it will first go to institutions capable of GMP-grade autologous mitochondrial separation, quality control, vitreous cavity injection, neuro-ophthalmic assessment, and regulatory submission; patients and investors bear the risks of insufficient evidence, unproven reproducibility, and lack of long-term safety data. Single-case physiological signals can enhance research attention but cannot serve as sufficient evidence for treatment efficacy, commercialization timelines, or biopharmaceutical valuations.
Source: Public Information
ABAB AI Insight
Bill Ackman's involvement in this project stems from his daughter Lucy's severe vision impairment and has led to the establishment of the $400 million Ackman Institute. Public reports indicate that he has urged doctors to try new approaches, including intraocular mitochondrial injections, during treatment decisions; this provides the research with rare patient family funding, public communication capabilities, and interdisciplinary resources, but also requires strict separation of personal observations from clinical evidence. The "immediate response" and "lasting but diminishing effects" observed in the single case can generate hypotheses for the next phase of research but cannot replace randomized controls, dose escalation, long-term follow-up, and independent replication.
The capital pathway is not traditional drug development: the research team isolates fresh, respirable mitochondria from the patient's own skeletal muscle, prepares them on-site, and delivers them to the eye via vitreous cavity injection. This pathway shifts the value chain from compound discovery and standardized drug production to tissue collection, active organelle separation, immediate quality control, cold chain or on-site operations, ophthalmic delivery, and functional measurement. To enter large-scale clinical trials, the most challenging aspects will be ensuring the activity, consistency, purity, dosage, delivery localization, and repeat dosing standards of each batch of mitochondria, rather than merely proving that a single injection can be completed.
Historically, gene therapy Luxturna provided a clear comparison for hereditary retinal diseases: it underwent target identification, clinical research, regulatory review, and FDA approval before becoming a commercial ophthalmic therapy; small clinical trials exploring ND4 gene therapy for Leber hereditary optic neuropathy have also been conducted. Mitochondrial transplantation is currently at an earlier stage, and related literature in the eye mainly comes from cellular and animal models. The first human attempts in 2026 showed that autologous mitochondria could be delivered to the eye and short-term physiological signals observed, but visual acuity was not restored, and the durability of efficacy and integration of intracellular function have not been confirmed.
Essentially, this is a challenge to the paradigm of drug development through technological substitution: traditional treatments often modulate pathological pathways through small molecules, antibodies, cells, or gene modifications; mitochondrial transplantation attempts to directly deliver the cell's energy factories to repair the functional gaps in neural tissue after metabolic failure. Its appeal lies in the high energy dependence of retinal neurons and the optic nerve, and the vitreous cavity provides a relatively accessible entry for local delivery; however, it cannot yet be considered a therapy because there is insufficient human data on whether exogenous mitochondria enter target cells, how long they survive, whether they truly enhance energy metabolism, and whether repeated injections accumulate risks. The future value will not be determined by a single pupil response but by reproducible functional improvements, durability, safety, and manufacturing consistency.
ABAB News · Cognitive Law
Single cases can open hypotheses but cannot close debates.
Physiological signals are not efficacy; repeated validation is efficacy.
The most cutting-edge treatments require the slowest evidence.